New England Peptide Unveils Proprietary Large Scale Peptide Synthesize
Want to listen to this article for FREE?
Complete the form below to unlock access to ALL audio articles.
Read time: Less than a minute
New England Peptide (NEP) has announced the introduction of a proprietary peptide synthesis instrument, PepScale™, to better enable peptide scale-up and process development projects for its customers.
The instrument is optimized for tens of grams and compliments NEP’s existing production capabilities. It was designed to provide the flexibility required for development work while taking advantage of the process efficiencies for which NEP has become known.
“At NEP, we pride ourselves at being a leader in peptide synthesis innovation,” said Ben Robinson, NEP’s Chief Operating Officer. “This proprietary instrument is a continued testament to our ability to create new products to meet our customers’ demands.”
The PepScale™ instrument was custom designed and built by NEP and incorporates the company’s chemistry knowledge at both a research and preclinical level. Based on the input of NEP’s highly experienced research and development team, NEP’s engineers designed the instrument to incorporate efficiencies and productivity that would benefit projects in early stage clinical development and API scale-up.
PepScale™‘s use of automation enables cost and time efficiencies to be realized when compared to manual synthesis, and also minimizes opportunities for human error.
The PepScale™ instrument, combined with the NEP development team’s extensive experience, helps customers work seamlessly with NEP from research and discovery through early stage development, including preclinical efforts. It provides a flexible option for manufacturing and scale-up that can cover the range of preclinical peptide API needs of their customers.
The instrument is optimized for tens of grams and compliments NEP’s existing production capabilities. It was designed to provide the flexibility required for development work while taking advantage of the process efficiencies for which NEP has become known.
“At NEP, we pride ourselves at being a leader in peptide synthesis innovation,” said Ben Robinson, NEP’s Chief Operating Officer. “This proprietary instrument is a continued testament to our ability to create new products to meet our customers’ demands.”
The PepScale™ instrument was custom designed and built by NEP and incorporates the company’s chemistry knowledge at both a research and preclinical level. Based on the input of NEP’s highly experienced research and development team, NEP’s engineers designed the instrument to incorporate efficiencies and productivity that would benefit projects in early stage clinical development and API scale-up.
PepScale™‘s use of automation enables cost and time efficiencies to be realized when compared to manual synthesis, and also minimizes opportunities for human error.
The PepScale™ instrument, combined with the NEP development team’s extensive experience, helps customers work seamlessly with NEP from research and discovery through early stage development, including preclinical efforts. It provides a flexible option for manufacturing and scale-up that can cover the range of preclinical peptide API needs of their customers.
